CMS Data on COVID Hospitalizations Underscores Need for Urgent Action to Protect Vulnerable Americans

American Kidney Fund urges Administration to release complete, nationwide data on pandemic impact

ROCKVILLE, MD / ACCESSWIRE / June 24, 2020 / The American Kidney Fund (AKF) today expressed deep concern about preliminary new data from the Centers for Medicare & Medicaid Services (CMS) indicating that end-stage renal disease (ESRD, or kidney failure) patients and Black Americans had vastly higher rates of hospitalization for COVID-19.

“The new CMS data on COVID hospitalizations among Medicare patients is the tip of the pandemic iceberg,” said LaVarne A. Burton, AKF president and CEO. “Racial and ethnic minorities are already disproportionately affected by kidney failure, and the double-whammy impact of COVID on Black Americans and those with kidney failure requires an urgent response from the federal government.”

According to the preliminary CMS data-which covers the period from January 1 to May 16-Blacks were nearly four times more likely than whites to be hospitalized with COVID-19, and Americans eligible for Medicare because they have ESRD had the highest COVID-19 hospitalization rate.

“It is absolutely urgent that we see all the data pertaining to the experience of minority populations with COVID-19, overlaid with chronic disease data to give us a full picture that will inform appropriate action to address the disproportionate impact,” Burton said.

More than half the dialysis patients in the United States are under 65, though most of them qualify for Medicare because of their kidney failure. People of all races and ethnicities develop chronic kidney disease (CKD) at similar rates, but minorities, including Blacks and Hispanic/Latinos, are more likely to progress to kidney failure. This disparity is evident in the racial and ethnic makeup of the low-income ESRD patients who receive financial assistance from AKF, including those receiving help from AKF’s Coronavirus Emergency Fund-most of those receiving grants are people of color.

About Us

The American Kidney Fund (AKF) fights kidney disease on all fronts as the nation’s leading kidney nonprofit. AKF works on behalf of the 37 million Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease-from prevention through transplant. With programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy, no kidney organization impacts more lives than AKF. AKF is one of the nation’s top-rated nonprofits, investing 97 cents of every donated dollar in programs, and holds the highest 4-Star rating from Charity Navigator and the Platinum Seal of Transparency from GuideStar.

For more information, please visit KidneyFund.org, or connect with us on Facebook, Twitter, Instagram and LinkedIn.

CONTACT:

Alice Andors
Senior Director of Communications
aandors@kidneyfund.org
11921 Rockville Pike, Suite 300, Rockville, MD 20852
Work: 240-292-7053 Mobile: 703-609-6085
KidneyFund.org

SOURCE: American Kidney Fund

View source version on accesswire.com:
https://www.accesswire.com/594986/CMS-Data-on-COVID-Hospitalizations-Underscores-Need-for-Urgent-Action-to-Protect-Vulnerable-Americans

Staff

Recent Posts

UOG (United One Group) Wins Three Prestigious Industry Awards at CES 2026

CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…

4 hours ago

Best Ipamorelin vs Sermorelin: Growth Hormone Peptide Comparison 2026 — ReadyRx Prescription Telehealth Analysis

Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…

7 hours ago

GLP-1 Booster From Health Journey: 2026 Ingredient Analysis And Probiotic Metabolic Support Explained

Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…

7 hours ago

MEDVi GLP-1 Investigation: What Consumer Data Shows About Compounded Telehealth Weight Loss Programs

Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…

7 hours ago

Best Peptides for Anti-Aging: NAD+ Delivery Methods Compared as Telehealth Platforms Expand Access (2026 Analysis)

Published NAD+ research examines cellular aging pathways and mitochondrial function as prescription peptide injection access…

7 hours ago

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a…

7 hours ago